Nanoparticulate Brain-Derived Neurotrophic Factor (BDNF) as a Potential Antidepressant via Neuroendocrine Mechanisms in Experimental Model of Depression
The hypothalamo-hypophyseal-adrenal axis (HHAA) links neurogenesis, neurotransmission, and immunoendocrine factors in depression. Stress-induced HHAA activation lowers brain-derived neurotrophic factor (BDNF) in the hippocampus, causing atrophic changes and depressive symptoms. Traditional antidepre...
| Main Author: | |
|---|---|
| Format: | Thesis |
| Language: | English English English |
| Published: |
Universiti Malaysia Sarawak
2025
|
| Subjects: | |
| Online Access: | http://ir.unimas.my/id/eprint/48563/ |
| Abstract | Abstract here |
| Summary: | The hypothalamo-hypophyseal-adrenal axis (HHAA) links neurogenesis, neurotransmission, and immunoendocrine factors in depression. Stress-induced HHAA activation lowers brain-derived neurotrophic factor (BDNF) in the hippocampus, causing atrophic changes and depressive symptoms. Traditional antidepressants increase BDNF, but BDNF cannot cross the blood-brain barrier. Nanocarriers aid delivery, yet nano-BDNF’s potential remains underexplored. This study examines nano-BDNF’s antidepressant effects in mice. Thirty C57BL/6 mice were divided into five groups: normal control, depression model, negative control, fluoxetine-treated, and nano-BDNF-treated. Behavioral tests, ELISA, and histological analysis assessed reserpine-induced depression. Results showed nano-BDNF and fluoxetine reversed depression effects, but nano-BDNF was superior in restoring HHAA function and immune balance. Histology confirmed nano-BDNF reversed adrenal and thymic changes linked to depression-induced immunosuppression. This study identifies nano-BDNF with poloxamer 188 as a promising antidepressant, comparable to fluoxetine in behavior recovery but superior in restoring HHAA balance. |
|---|